EXEL
EXELIXIS, INC.
NASDAQ · Healthcare · Biotechnology · US
$58.36
−0.22%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$58.50
From 52W high−1.30%
Volume5.19M
Market cap$14.46B
P/E (TTM)17.7x
P/S (TTM)5.9x
Div yield—
Key dataSep 18, 2026
Open
$58.50
From 52W high
−1.30%
Volume
5.19M
Market cap
$14.46B
ValuationView details →
P/E (Fwd)
15.8x
EV/EBITDA
13.3x
P/E (TTM)
17.7x
RSI (14)
57.8
MomentumView details →
1D Return
−0.22%
YTD Return
+32.54%
SummaryUpdated Jul 1, 2026
Exelixis, Inc. (NASDAQ:EXEL) is an oncology-focused biotechnology company founded in 1994 and headquartered in Alameda, California. Originally incorporated as Exelixis Pharmaceuticals, Inc., the company changed its name to Exelixis, Inc. in February 2000 and went public that same year. What began as a drug discovery company has evolved into a leading commercial-stage biotechnology firm specializing in cancer treatments. Today, Exelixis has successfully transitioned from a research-focused organization to a profitable company with multiple approved cancer therapies and a robust pipeline of experimental treatments targeting various solid tumors.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration extended by three months its review of Exelixis' experimental colorectal cancer drug combination, as disclosed by Exelixis in a filing on Friday.9d agoHanda Biotechnology announced that its new anticancer drug HND-039 (Omcazio capsules) received final approval from the US FDA, allowing it to enter the US market, with the originator's patent expiring in late August and a citizen petition dismissed.16d ago